Review: The Role of Cytokines in the Catabolic Consequences of Infection and Injury

Journal of Parenteral and Enteral Nutrition - Tập 22 Số 3 - Trang 156-166 - 1998
Huilan Chang1, Bruce R. Bistrian1
1From the Laboratory of Nutrition/Infection, Cancer Research Institute, Department of Medicine, Beth Israel Deaconess Medical Center, West Campus, Harvard Medical School, Boston

Tóm tắt

During infection and injury a series of metabolic events are activated that leads to a state of negative nitrogen balance and significant loss of lean body mass. This process is characterized by marked anorexia, net whole body protein breakdown, and liver anabolism. This host response initially is beneficial to the body because it helps it to fight disease and enhance healing. However, if such imbalance is maintained for long periods, it will invariably produce significant loss of lean body mass that may lead to a series of untoward clinical events. The role of the proximate cytokines, tumor necrosis factor (TNF), interleukin‐1 (IL‐1), and interleukin‐6 (IL‐6) as well as glucocorticoids as important mediators of many pathophysiological manifestations of infection and injury has been studied extensively. However, the involvement of other mediators, at least in skeletal muscle proteolysis during sepsis has been hypothesized, because blockade of glucocorticoids, TNF, IL‐1, and IL‐6 reduces but does not normalize protein breakdown rates nor does the direct application of these mediators to skeletal muscle in vitro enhance proteolysis. Furthermore other studies have suggested that the lymphokine, interferon‐gamma (IFN‐γ, type II interferon or immune interferon), produces fever and enhances thermogenesis, body weight loss, and skeletal muscle depletion in rodents in a manner similar to that seen with TNF and IL‐1. Cytokines appear to be major components of the host metabolic response during infection and injury. However, neither all the cytokines involved nor the exact mechanisms underlying their metabolic effects are completely understood. The regulation of muscle protein synthesis and breakdown, which largely determines the development of cachexia, appears to depend on the delicate balance between a number of regulatory substances including cytokines, glucocorticoids, catecholamines, insulin, and insulin‐like growth factors. (Journal of Parenteral and Enteral Nutrition 22:156–166, 1998)

Từ khóa


Tài liệu tham khảo

10.1126/science.3895437

10.1038/330662a0

10.1073/pnas.88.23.10535

10.1002/eji.1830211134

10.1084/jem.175.1.91

10.1038/364798a0

10.1016/0092-8674(93)90134-C

10.1016/0092-8674(87)90028-6

10.1172/JCI114937

Buck M., 1996, Tumor necrosis factor‐α inhibits collagen α 1(I) gene expression and wound healing in a murine model of cachexia, Am J Pathol, 149, 195

10.1172/JCI114059

10.1172/JCI113466

Dinarello CE, 1991, Interleukin‐1 and interleukin‐1 antagonism, Blood, 77, 1627, 10.1182/blood.V77.8.1627.1627

10.1038/348550a0

10.1084/jem.173.4.1029

Gauldie J., 1987, Purified interleukin‐1 (IL‐1) from human monocytes stimulates acute‐phase protein synthesis by rodent hepatocytes in vitro, Immunology, 60, 203

Warner SJC, 1987, Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells, J Immunol, 139, 1911, 10.4049/jimmunol.139.6.1911

10.1084/jem.163.6.1433

10.1084/jem.164.6.2113

Ruschen S., 1989, Spontaneous and LPS‐stimulated production of intracellular IL‐1β by sinovial macrophages in rheumatoid arthritis is inhibited by IFN‐γ, Clin Exp Immunol, 76, 246

Ghezzi P., 1988, IL‐1 induces IL‐1. III. Specific inhibition of IL‐1 production by IFN‐γ, J Immunol, 140, 4238, 10.4049/jimmunol.140.12.4238

Knudsen PJ, 1987, Glucocorticoids inhibit transcriptional and post‐transcriptional expression of interleukin‐1 in U937 cells, J Immunol, 139, 4129, 10.4049/jimmunol.139.12.4129

Knudsen PJ, 1984, Prostaglandins inhibit post‐transcriptional interleukin‐1 synthesis by increasing intracellular cyclic adenosine monophosphate, J Immunol, 137, 3189, 10.4049/jimmunol.137.10.3189

10.1056/NEJM198303103081002

10.1097/00000658-199209000-00018

10.1016/S0065-2776(08)60532-5

Richards C., 1991, Cytokine control of acute phase protein expression, Eur Cytokine Network, 2, 89

10.1038/368339a0

10.1016/S0006-291X(88)81305-6

10.1073/pnas.89.22.10998

10.7326/0003-4819-119-8-199310150-00001

10.1172/JCI115767

10.1002/eji.1830230824

10.1084/jem.169.6.2257

Jablons DM, 1989, IL‐6/IFN‐β‐2 as a circulating hormone. Induction by cytokine administration in humans, J Immunol, 142, 1542, 10.4049/jimmunol.142.5.1542

10.1146/annurev.iy.11.040193.003035

Watson J., 1978, The genetic mapping of a defective LPS response gene in C3H/HeJ mice, J Immunol, 120, 422, 10.4049/jimmunol.120.2.422

10.1007/BF01843983

Freudenberg MA, 1993, Bacterial Endotoxins: Recognition and Effector Mechanisms, 197

Katschinski T., 1992, Gamma interferon mediates Propionibacterium acnes‐induced hypersensitivity to lipopolysaccharide in mice, Infect Immun, 60, 1994, 10.1128/iai.60.5.1994-2001.1992

Wherry JC, 1991, Regulation of gamma interferon production by natural killer cells in scid mice : Roles of tumor necrosis factor and bacterial stimuli, Infect Immun, 59, 1709, 10.1128/iai.59.5.1709-1715.1991

10.1084/jem.181.3.953

Freudenberg MA, 1991, Tumor necrosis factor alpha mediates lethal activity of killed Gram‐negative and Gram‐positive bacteria in D‐galactosamine‐treated mice, Infect Immun, 59, 2110, 10.1128/iai.59.6.2110-2115.1991

Freudenberg MA, 1991, Gamma interferon production in endotoxin‐responder and non‐responder mice during infection, Infect Immun, 59, 3484, 10.1128/iai.59.10.3484-3491.1991

Heinzel FP, 1990, The role of IFN‐γ in the pathology of experimental endotoxemia, J Immunol, 145, 2920, 10.4049/jimmunol.145.9.2920

Doherty GM, 1992, Evidence for IFN‐γ as a mediator of the lethality of endotoxin and tumor necrosis factor‐α, J Immunol, 149, 1666, 10.4049/jimmunol.149.5.1666

Bucklin SE, 1994, Participation of IFN‐γ in the pathogenesis of LPS lethality, Prog Clin Biol Res, 338, 399

Kohler J., 1993, IFN‐γ involvement in the severity of gram‐negative infections in mice, J Immunol, 151, 916, 10.4049/jimmunol.151.2.916

10.1093/infdis/166.2.331

10.1084/jem.171.6.1853

10.1002/eji.1830230924

10.1084/jem.179.5.1437

10.1084/jem.178.4.1435

10.1126/science.8456301

10.1073/pnas.82.21.7404

Zhao Y., 1995, Impact of interferon‐γ receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis, J Immunol, 155, 5736, 10.4049/jimmunol.155.12.5736

Flynn JL, 1993, An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection, J Exp Med, 178, 2249, 10.1084/jem.178.6.2249

10.1073/pnas.90.14.6626

10.1084/jem.171.2.455

10.1016/0016-5085(94)90604-1

Matthys P., 1995, Anti‐gamma interferon and anti‐interleukin‐6 antibodies affect staphylococcal enterotoxin B‐induced weight loss, hypoglycemia, and cytokine release in D‐galactosamine‐sensitized and unsensitized mice, Infect Immun, 63, 1158, 10.1128/iai.63.4.1158-1164.1995

10.1002/ijc.2910490115

Langstein HN, 1991, The roles of γ‐interferon and tumor necrosis factor α in an experimental model of cancer cachexia, Cancer Res, 51, 2302

10.1016/0277-5379(91)90483-T

10.1093/jnci/82.3.208

10.1007/BF00199382

Krigel RL, 1988, A phase I study of recombinant interleukin 2 plus recombinant β‐interferon, Cancer Res, 48, 3875

Legaspi A., 1985, Proteolysis of skeletal muscle in response to acute elevation of plasma cortisol in man, Surg Forum, 36, 16

Kayali AG, 1987, Sensitivity of myofibrillar protein to glucocorticoid‐induced muscle proteolysis, Am J Physiol, 252, E621

10.1016/0022-4804(90)90077-F

10.1016/0026-0495(89)90100-5

Nelson DH, 1989, Endocrinology, Vol II, 1660

Baumann H., 1987, Interaction among hepatocyte‐stimulating factors, interleukin‐1, and glucocorticoids for regulation of acute phase proteins in human hepatoma (Hep G2) cells, J Immunol, 139, 4122, 10.4049/jimmunol.139.12.4122

Hall‐Angeras M., 1991, Effect of the glucocorticoid receptor antagonist RU 38486 on muscle protein breakdown in sepsis, Surgery, 109, 468

10.1016/0022-4804(91)90045-N

Zamir O., 1993, Effects of tumor necrosis factor or interleukin‐1 on muscle amino acid uptake and the role of glucocorticoids, Surg Gynecol Obstet, 177, 27

Philibert D., RI 38486: An original multifaceted antihormone in vivo. IN Adrenal Steroid Antagonism, 77

10.1172/JCI117551

10.1126/science.7725095

10.1056/NEJM199612193352507

Baracos VE, 1995, Activation of the ATP‐ubiquitin‐proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma, Am J Physiol, 268, E996

Price SR, 1994, Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNA in rat muscle, Am J Physiol, 267, C955, 10.1152/ajpcell.1994.267.4.C955

10.1172/JCI118968

Price SR, 1996, Necessary but not sufficient: The role of glucocorticoids in the acidosis‐induced increase in levels of mRNAs encoding proteins of the ATP‐dependent proteolytic pathway in rat muscle, Miner Electrolyte Metab, 22, 72

10.1073/pnas.93.5.1967

10.1172/JCI117588

10.1172/JCI118421

10.1172/JCI119143

Wing SS, 1994, 14‐kDa ubiquitin‐conjugating enzyme: Sructure of the rat gene and regulation upon fasting and by insulin, Am J Physiol, 267, E39

10.1146/annurev.bi.61.070192.003553

10.1007/BF00990972

10.1007/BF00990968

10.1006/bbrc.1995.2848

10.1172/JCI118586

10.1002/dmr.5610040805

10.3181/00379727-200-43423

Ling PR, 1996, Metabolic changes in rats during a continuous infusion of recombinant interleukin 1, Am J Physiol, 270

Ling PR, 1997, Mechanisms of host wasting induced by administration of cytokines in rats, Am J Physiol, 272, E333

Darling G., 1990, Cachectic effects of recombinant human tumor necrosis factor in rats, Cancer Res, 50, 4008

10.1001/archsurg.1992.01420020052008

10.1016/0020-711X(94)90088-4

10.3181/00379727-205-43695

10.1042/cs0890431

10.1210/endo-128-5-2657

10.1006/bbrc.1995.1168

10.1172/JCI118398

10.1084/jem.183.1.311

Fattori E., 1994, Defective inflammatory response in interleukin‐6‐deficient mice, J Exp Med 1994;, 180, 1243

Kozak W., 1997, Sickness behavior in mice deficient in interleukin‐6 during turpentine abscess and influenza pneumonitis, Am J Physiol, 272, R661

10.1006/bbrc.1996.0651

Hall‐Agnerås M., 1990, Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis, Surgery, 108, 460

10.1001/archsurg.1990.01410130044006

Tessitore L., 1994, Pharmacological interference with cancer cachexia, Biochem J, 299, 71

Hotamisligil GS, 1994, Tumor necrosis factor α: A key component of the obesity‐diabetes link, Diabetes, 43, 1271, 10.2337/diab.43.11.1271

10.1172/JCI118504

Breuillé D., 1993, Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis, Am J Physiol, 265, E660

10.1016/S0092-8674(94)90482-0

Lang CH, 1992, Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output, Endocrinology, 130, 43, 10.1210/endo.130.1.1727716

Douglas RG, 1991, Effects of recombinant IGF‐I on protein and glucose metabolism in rTNF‐infused lambs, Am J Physiol, 261, E606

Olefsky JM, 1990, Diabetes Mellitus, 121

10.1172/JCI118469

Kadowaki M., 1996, Acute effect of epinephrine on muscle proteolysis in perfused rat hindquarters, Am J Physiol, 270, E961

10.1007/BF01119805

10.1016/0305-4179(93)90097-R

10.1172/JCI117929

10.1016/0304-3835(95)03858-T

Cooney RN, 1994, Interleukin‐1 receptor antagonist prevents sepsis‐induced inhibition of protein synthesis, Am J Physiol, 267, E636

Jurasinki CV, 1995, Insulin‐like growth factor I accelerates protein synthesis in skeletal muscle during sepsis, Am J Physiol, 269, E977

Lang CH, 1996, IL‐1 receptor antagonist attenuates sepsis‐induced alterations in the IGF system and protein synthesis, Am J Physiol, 270, E430

10.1097/00024382-199507000-00003

10.1210/endo.134.4.7511091

Wojnar MM, 1995, Alterations in the insulin‐like growth factor system in trauma patients, Am J Physiol, 268, R970

10.1007/BF00926520

Fan J., 1995, Regulation of insulin‐like growth factor (IGF)‐I and IGF‐binding proteins by tumor necrosis factor, Am J Physiol, 269, R1204

Fan J., 1995, Regulation of insulin‐growth factor (IGF)‐I mRNA and peptide, and IGF‐I binding proteins by interleukin‐1, Am J Physiol, 270, R621

Dardevet D., 1994, Insulin‐like growth factor‐1 and insulin resistance in skeletal muscle of adult and old rats, Endocrinology, 134, 1475, 10.1210/endo.134.3.8119189

10.2527/1994.7292279x

Vary TC, 1996, Regulation of peptide‐chain initiation in muscle during sepsis by interleukin‐1 receptor antagonist, Am J Physiol, 271, E513

Cooney RN, 1995, Prevention of skeletal muscle catabolism in sepsis does not impair visceral protein metabolism, Am J Physiol, 270, E621

Lang CH, 1996, Central interleukin‐1 partially mediates endotoxin‐induced changes in glucose metabolism, Am J Physiol, 271, E309

Jefferson LS, 1974, Insulin in the regulation of protein turnover in heart and skeletal muscle, Fed Proc, 33, 1098

Fulks R., 1975, Effects of insulin, glucose and amino acids on protein turnover in rat diaphragm, J Biol Chem, 250, 290, 10.1016/S0021-9258(19)42013-9

Narahara HT, 1974, The actions of insulin, trypsin and electrical stimulation on amino acid transport in muscle, J Biol Chem, 249, 5435, 10.1016/S0021-9258(20)79747-4

10.1007/BF00260962

10.1016/0026-0495(80)90158-4

10.2337/diab.38.9.1117

10.1016/0026-0495(90)90033-9

Larbaud D., 1996, Euglycemic hyperinsulinemia and hyperaminoacidemia decrease skeletal muscle ubiquitin mRNA in goats, Am J Physiol, 271, E505

10.1073/pnas.91.11.4854

10.1016/0006-291X(89)91088-7

10.1172/JCI117495

Jepson MM, 1988, Relationship between glutamine concentration and protein synthesis in rat skeletal muscle, Am J Physiol, 255, E166

10.1016/0012-1606(88)90348-X

Karner J., 1989, Glutamine‐containing dipeptides as infusion substrates in the septic state, Surgery 1989;, 106, 893

Hickson RC, 1996, Glutamine interferes with glucocorticoid‐induced expression of glutamine synthetase in skeletal muscle, Am J Physiol, 270, E912

10.1056/NEJM198303103081001

McDevitt TM, 1995, Purification and characterization of a lipid‐mobilizing factor associated with cachexia‐inducing tumors in mice and humans, Cancer Res, 55, 1458

10.1038/379739a0

10.1111/j.1432-1033.1992.tb19822.x